Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

Stereotaxis (NYSE: STXS) will release fourth quarter and full year 2025 financial results on Monday, March 9, 2026 after U.S. market close and host a conference call and webcast at 4:30 p.m. ET.

Rhea-AI Summary

Stereotaxis (NYSE: STXS) will release fourth quarter and full year 2025 financial results on Monday, March 9, 2026 after U.S. market close and host a conference call and webcast at 4:30 p.m. ET.

Investors can dial in using U.S./Canada number 800-715-9871 or international 646-307-1963 with pass code 8365695, and a webcast and one-month phone replay will be available via the company investor relations site.

Argus Feb 12 session

-0.49% close to close Open Argus

Details

News Market Reaction – STXS

On Feb 12, the day this news came out, STXS closed 0.49% below the previous close.

Data tracked by StockTitan Argus for the Feb 12 session.

Key Figures

Earnings release date: March 9, 2026 Conference call time: 4:30 p.m. ET Patients treated: over 150,000 patients

Earnings release date

March 9, 2026

Scheduled 2025 Q4 and full-year financial results release

Conference call time

4:30 p.m. ET

Start time for Q4 and full-year 2025 earnings call

Patients treated

over 150,000 patients

Cumulative global use of Stereotaxis technology

Historical Context

5 past events · Latest: Feb 09

5 events

1. Feb 09

   New EP program

   24h Move

   +4.4%

   German hospital established a Genesis robotic heart arrhythmia program.

2. Jan 06

   FDA approval

   24h Move

   +8.1%

   FDA approved MAGiC ablation catheter for robotic electrophysiology use.

3. Nov 24

   Conference participation

   24h Move

   +1.7%

   Participation in major healthcare conference highlighting growth and milestones.

4. Nov 11

   Q3 2025 earnings

   24h Move

   +2.1%

   Reported Q3 results with >20% expected 2025 revenue growth and new clearances.

5. Nov 10

   FDA clearance

   24h Move

   +2.6%

   GenesisX robotic system received FDA 510(k) clearance and limited launch began.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

surgical robotics, minimally invasive endovascular intervention, webcast

3 terms

surgical robotics technical

"a pioneer and global leader in surgical robotics for minimally invasive endovascular"

Surgical robotics are computer-guided machines—robotic arms, cameras and software—that assist surgeons by increasing steadiness, precision and access during operations, acting like a highly controlled extension of a surgeon’s hands. Investors pay attention because these systems can reshape hospital spending, create recurring revenue from instruments, software and service contracts, and their commercial success depends on clinical outcomes, regulatory approval and how quickly hospitals adopt the technology.

minimally invasive endovascular intervention medical

"surgical robotics for minimally invasive endovascular intervention, today announced"

A minimally invasive endovascular intervention is a medical procedure that treats blood vessel problems from inside the vessel using thin tubes, wires and small tools threaded through a tiny puncture instead of large surgical cuts; think of fixing plumbing by inserting tools through the pipes rather than tearing out walls. It matters to investors because these procedures typically cut hospital stays, lower complication rates and can expand patient access, which affects device sales, procedure volumes and healthcare costs.

webcast technical

"The Company will host a conference call and webcast at 4:30 p.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

What:	Stereotaxis fourth quarter and full year 2025 financial results conference call
When:	Monday, March 9, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Dial In Number:	To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 8365695.
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
Call Replay:	A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery                    
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Stereotaxis (STXS) report fourth quarter and full year 2025 results?

Stereotaxis will report results on Monday, March 9, 2026 after U.S. market close at 4:30 p.m. ET. According to Stereotaxis, management will discuss financial results and corporate developments during the conference call and webcast that day.

How can investors join the Stereotaxis (STXS) March 9, 2026 conference call?

Investors can dial 800-715-9871 (US/Canada) or 646-307-1963 (International) and enter pass code 8365695. According to Stereotaxis, the call begins at 4:30 p.m. ET and a live webcast will also be available on the investor relations website.

Where can I access the Stereotaxis (STXS) live webcast and replay for the March 9, 2026 call?

The live webcast and replay are available on Stereotaxis’ investor relations website at http://ir.stereotaxis.com/. According to Stereotaxis, a phone replay will also be available for one month beginning about four hours after the call ends.

What will Stereotaxis (STXS) management cover during the March 9, 2026 call?

Management will discuss the company’s fourth quarter and full year 2025 financial results and corporate developments. According to Stereotaxis, the presentation aims to review performance metrics and recent business updates with investors and analysts.

Who should investors contact for questions about Stereotaxis (STXS) investor relations?

Investors can reach the company at 314-678-6100 or via Investors@Stereotaxis.com for investor queries. According to Stereotaxis, David L. Fischel and Kimberly Peery are listed as investor contacts for further information.